I received my B.S. and Ph.D. from National Taiwan University and Georgia Tech in chemistry. I received an Oak Ridge Fellowship for my postdoctoral training at the Massachusetts Institute of Technology. In 2018, I joined Genentech's Synthetic Molecule Pharmaceutical Science department (SMPS). I led the development of preformulation and formulation support for novel modalities, including peptides, oligonucleotides, mRNA, etc. In 2020, we started building the understanding of drug delivery approaches for the undruggable targets.
The postdoctoral mentor program at Genentech offers a unique opportunity to pursue fundamental science and work closely with the next generation of researchers. The discoveries of postdoctoral research could influence future drug development.
ACS Nano 2023, 17, 11454-11465.
Int J Pharm 2023, 637, 122874
Molecular Therapy Nucleic Acids, 2023, 32, 773-793
Expert Opinion on Drug Delivery, 2023, 16, 118
Adv. Therapeutics;, 2022, 2200207
American Pharmaceutical Review, Oct 2022
Anal. Chem., 2022, 94, 2032
Nanoscale Adv., 2022, 4, 2107
AAPS PharmSciTech, 2022, 23, 28
Chapter 4 of Implantable Technologies: Drug Delivery for Peptides, Biologics and Small Molecules by Royal Society of Chemistry, 2021
The AAPS Journal 2021, 23(6), 111
Int J Pharm 2021, 607, 120980
Int J Pharm 2021, 599, 120392
J. Pharm Sci 2021, 110(6), 2362
At Genentech, I lead a group focusing on the delivery strategies of novel modalities. In particular, we are interested in leveraging cutting-edge formulation and characterization techniques for pipeline support.